If it's internally developed, one would certainly to expect to find them as an assignee on something with those terms, seeing as it is a purported CB2 agonist. But I don't follow Arena these, days, so I don't where they got the molecule from. Edit: A quick PubMed search indicates it is internally developed, so the apparent lack of IP is very odd. Have fun sleuthing! Maybe a quick question to Arena's IR would get you pointed in the right direction?
Edit2: Seeing on twitter that there isn't much dose response. Didn't read the PR to see how positive the data (safety/efficacy) really was. Perhaps they just need to explore the low end of the range more . . . "just". Haha, pain trials . . .
I was apparently talking to the COO of CohBar, who was responding on a Saturday, so despite the gung-ho-ness of the guy, he had some combination of a) limited knowledge, b) limited resources on a weekend (couldn't ask anyone more knowledgeable), or c) was reluctant to disclose further details about dosing to an individual at this point. I don't know if I'll get any further details out of him. I am curious about the program, so I guess I'll just keep checking clinicaltrials.gov every week or so. Still no position in CWBR.
Cheers, Tuck |
